A5087209951- Glaucoma and retinal disorders
- Corneal surgery and disorders
- Intraocular Surgery and Lenses
- Retinal Diseases and Treatments
- Retinal and Macular Surgery
- Ophthalmology and Visual Impairment Studies
- Ocular Surface and Contact Lens
- Ophthalmology and Eye Disorders
- Retinal Imaging and Analysis
- Ocular Infections and Treatments
- Cerebral Venous Sinus Thrombosis
- Global Health Workforce Issues
- Cerebrovascular and Carotid Artery Diseases
- Schizophrenia research and treatment
- Traumatic Ocular and Foreign Body Injuries
- Retirement, Disability, and Employment
- Psychosomatic Disorders and Their Treatments
- Health disparities and outcomes
- Mental Health Treatment and Access
- Health Systems, Economic Evaluations, Quality of Life
- Corneal Surgery and Treatments
- Cultural Competency in Health Care
- Migration, Aging, and Tourism Studies
- Ocular Oncology and Treatments
- Ophthalmology and Visual Health Research
Prism Eye Institute
2016-2025
University of Utah
2007-2025
University of Toronto
2016-2025
University of Hawaiʻi at Mānoa
2004-2025
University of Hawaii System
2007-2025
Uniformed Services University of the Health Sciences
2013-2025
Baghdad Medical City
2025
Khulna University
2020-2024
Trillium Health Centre
2015-2024
Georgetown University Medical Center
2024
Purpose: The purpose of this study was to describe the fluidics a novel non-valved glaucoma implant designed prevent hypotony and compare device with two commonly used devices. Methods: XEN 45 micro-fistula limit by virtue its length width according Hagen-Poiseuille equation. Flow testing performed using syringe pump pressure transducer at multiple flow rates. differentials across implant, Ex-Press 10 mm silicone tubing from Baerveldt physiologic rate (2.5 μL/min) were extrapolated. Results:...
To evaluate the efficacy of multiple trabecular micro-bypass stents combined with cataract surgery in patients open-angle glaucoma (OAG) and cataract.Private practice, Mississauga, Ontario, Canada.Comparative case series.Eyes OAG had implantation 2 or 3 concurrent follow-up through 1 year. Efficacy measures were intraocular pressure (IOP) topical ocular hypotensive medication use. Safety assessment included complications corrected distance visual acuity (CDVA).The study comprised 53 eyes (47...
Abstract Importance The transscleral XEN Glaucoma Gel Microstent (XEN‐GGM, Allergan Plc., Parsippany, New Jersey) is implanted by a minimally invasive ab interno technique. Background present study aims to assess the long‐term clinical outcomes in patients after XEN‐GGM implantation. Design This prospective, non‐randomized, multi‐centred was conducted three countries (Austria, Canada and Germany). Participants Sixty‐four consecutive eyes of 64 with open angle glaucoma received (63 μm)...
To evaluate the intraocular pressure (IOP) lowering effect of XEN140 microfistula gel stent implant for surgical treatment open-angle glaucoma.Forty-nine eyes 49 patients with an IOP>18 mm Hg and ≤35 were studied in a prospective nonrandomized multicenter cohort trial implantation glaucoma. Complete success was defined as postoperative IOP≤18 ≥20% reduction IOP at 12 months without any glaucoma medications. Failure vision loss light perceptions or worse, need additional surgery, <20% from...
Purpose To study the effect on intraocular pressure (IOP) of implanting a new gelatin stent at time cataract surgery in treatment open-angle glaucoma (OAG). Setting Multicenter university and private-practice settings. Design Nonrandomized prospective clinical trial. Methods The implantation 2 models (Xen140 Xen63) was performed without mitomycin-C. Complete success defined as postoperative IOP less than 18 mm Hg more 20% reduction 12 months medication. Failure loss light perception vision...